Recent advances in treatment of nodal and gastrointestinal follicular lymphoma

Table 5 Summary of Clinical Trial Results of Bruton’s Tyrosine Kinase inhibitors

Study	Target disease	No. of patients	Objective response rate	Complete response rate	Progression-free survival	Overall survival	Adverse events or others	Ref.
Zanubrutinib (other BTKi) alone	r/r FL		36.4%	18.2%	Median PFS 10.4 mo (median follow-up 33.9 mo)	Unknown		[42]
Zanubrutinib phase-II	r/r MCL	83.7%	77.9%	Unknown	33.0 mo	Unknown		[43]
	r/r FL	n = 100	21.0% (poor)	Unknown	Unknown	Unknown		[47]
Ibrutinib with rituximab phase-II trial	Untreated FL, r/r FL	n = 13, n = 27	85% (arm-1), 75% (arm-2)	Unknown	62% of untreated FL, 26% of r/r FL, continued treatment	Unknown		[48]

“Unknown” means data not shown, unknown information or not reached. r/r: Refractory and relapsed; FL: Follicular lymphoma; MCL: Mantle cell lymphoma; PFS: Progression-free survival.